Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version)
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
EU legal act incorporated into the EEA Agreement by a Joint Committee Decision (JCD) Area (EEA Agreement)
XVII Intellectual Property
Joint committee decision (JCD)
092/2017 In force in the EEA
Yes Legal documents
Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version)
Reglugerð Evrópuþingsins og ráðsins (EB) nr. 469/2009 frá 6. maí 2009 um vottorð um viðbótarvernd fyrir lyf (kerfisbundin útgáfa)
Verordnung (EG) Nr. 469/2009 des Europäischen Parlaments und des Rates vom 6. Mai 2009 über das ergänzende Schutzzertifikat für Arzneimittel (kodifizierte Fassung)
Europaparlaments- og rådsforordning (EF) nr. 469/2009 av 6. mai 2009 om det supplerende beskyttelsessertifikatet for legemidler
History
01.06.2018
Adopted JCD confirmed entry into force date
01.06.2018
Compliance date in the EEA
11.09.2017
Constitutional requirements under Art. 103 fulfillment date (NO)
Norway
12.04.2018
Constitutional requirements under Art. 103 fulfillment date (IS)
Iceland
05.05.2017
Adoption of Joint Commitee Decision (JCD) incorporating the act into the EEA Agreement
30.11.2007
Draft Joint Commitee Decision (JCD) incorporating the act into the EEA Agreement sent to Commission
06.05.2009
Adoption date in the EU
06.07.2009
Compliance date in the EU
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.